双鹭药业上半年净利1.21亿元，同比增长309.08%

Core Viewpoint - The financial performance of Shuanglu Pharmaceutical in the first half of 2025 shows a significant decline in revenue but a substantial increase in net profit, primarily due to changes in the fair value of financial assets [1] Financial Performance Summary - The company reported a revenue of 305 million yuan, representing a year-on-year decrease of 22.24% [1] - The net profit attributable to shareholders reached 121 million yuan, marking a year-on-year increase of 309.08% [1] - The non-recurring net profit was approximately 26 million yuan, reflecting a year-on-year decline of 78.42% [1] Factors Influencing Performance - The substantial increase in net profit is attributed to the fair value changes of trading financial assets and other non-current financial assets held during the reporting period [1] - The decline in non-recurring net profit is primarily due to intensified competition in the pharmaceutical industry, price reductions from centralized procurement, and rising operating costs, which collectively impacted revenue negatively [1]